<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>WRITTEN EVIDENCE SUBMITTED BY THE VETERINARY MEDICINES DIRECTORATE (VMD) TO THE HOUSE OF COMMONS SCIENCE AND TECHNOLOGY SELECT COMMITTEE INQUIRY INTO ANTIMICROBIAL RESISTANCE</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by the Veterinary Medicines Directorate (VMD) (AMR0047)</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">The VMD and the reasons for submitting evidence</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The VMD is an Executive Agency of the Department for the Environment, Food and Rural Affairs (Defra).  It is the regulatory body for the UK for veterinary medicines and is policy lead within Defra for such medicines.   Antimicrobial medicines are part of its responsibilities, as is ensuring surveillance of antibiotic resistance in veterinary pathogens, and in food-borne bacteria that may cause harm to people.  It also has a very small budget from which it can commission research. The VMD worked closely with the Department of Health in the development of the Government’s new national strategy on antimicrobial resistance (https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018).</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q1. How has antimicrobial resistance developed in the past decade?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify; text-indent:201pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For veterinary specific pathogens the evidence on changing patterns of susceptibility is much sparser than that for human pathogens.  Within Europe, one of the reasons for this is that there is a scheme for pan-European surveillance of selected human clinical bacterial isolates as well as a tradition of hospitals publishing results in the science literature.  There is significantly less published evidence on resistance in the community.  For veterinary pathogens there is as yet no pan-European surveillance scheme, and only a few national schemes. The UK is one of the few countries with a comprehensive national scheme for surveillance of antibiotic susceptibility in veterinary bacteria.  The findings reflect those of other countries.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Data from UK surveillance of the susceptibility of veterinary pathogens show that levels of resistance are low, especially for the antibiotics that have been in use for many years (recent surveillance results will be published shortly on the VMD website: http://www.vmd.defra.gov.uk/). There is some evidence of increasing resistance in turkeys and to a lesser extent in chickens for some bacterial-antibiotic combinations. Third generation cephalosporins are an important first-line treatment in human medicine and resistance to such compounds mediated by extended-spectrum beta-lactamases (ESBLs) was first detected in the last decade in farm animals in the UK and appears to be slowly increasing. Penicillin resistance has also been detected in a few veterinary streptococci for the first time in the last decade, notably in </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Streptococcus suis</span><span style="font-family:'Times New Roman'; font-size:11pt">, which causes meningitis in pigs and is also a zoonosis. Swine dysentery is a diarrhoeal disease of pigs which does not affect man and for which a limited number of antibiotics are available for treatment. Resistance to all of these compounds has been noted in a handful of pig herds in recent years and since no treatment is available, these herds have had to be depopulated (killing all their pigs) and the premises left “fallow” for an interval to allow residual infection to die out. Generally, notwithstanding this last important exception, there is little evidence of widespread multi-drug resistance in veterinary pathogens, and resistance to therapeutic levels of critically important antibiotics for humans remains very low. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify; text-indent:36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is reassuring that traditional antibiotics e.g. penicillins and tetracyclines (older antibiotics, some of which have lost most of their usefulness in human medicine) are still the mainstay of veterinary treatment, and resistance has yet to emerge as a significant problem in livestock production.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is mandatory surveillance across Europe of changing patterns of susceptibility to antibiotics of food-borne bacterial pathogens namely types of salmonella and campylobacter and </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Escherichia coli (E.coli).</span><span style="font-family:'Times New Roman'; font-size:11pt">  Extensive analysis in the UK (five times more than the minimum mandated) has shown little emergence of resistance in salmonella over the last 10 years.  For 2011, of 2862 isolates of salmonella tested only 14 (0.5%) and 6 (0.2%) were resistant respectively to ciprofloxacin and ceftazidime/cefotaxime (antibiotics important in the treatment of serious salmonella infection).</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">An important point here is that these figures are in the context of expected resistance (failure to respond to therapy) for treatment doses recommended to treat human cases when required (clinical break-point).  Many reports quote figures for resistance where it is defined as less susceptible than a proportion of the bacterial population (epidemiological cut-off value).  A simple analogy is some people will be heavier than the majority of the population (cf. cut-off value) and some so heavy their weight poses a risk to their health (cf. break-point value).  This distinction is more than an exercise in semantics in that the word “resistance” in the context of antibiotics, and antimicrobials in general, is used interchangeably by professionals despite non-specialists understanding the word only to mean no longer treatable.  Certain published figures can therefore be unduly alarming.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q2. What are the gaps in our knowledge about antimicrobial resistance?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There are many gaps.  More is unknown than known.  The ways bacteria can develop resistance are many and varied, as are mechanisms that some of the resistance capabilities can be transferred to other bacteria.  There is currently no way to predict with any measure of certainty the likelihood of a resistance emerging, the likelihood of persistence, or the risk of transfer of that resistance and its survival in a new bacterial population, especially as not all bacteria behave the same way. If one considers the different mechanisms of action of different antibiotics, the consequence of using more than one antibiotic simultaneously, and other compounds (e.g. disinfectants, heavy metals) that may select for resistance mechanisms that could protect bacteria against antibiotics, it becomes evident that it is a very complex area. However, knowing whether there is a particular dose of antibiotic (or antibiotic combination) that is both therapeutically effective and minimises the risk of selection of resistance would be helpful.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Although there is still a need for further and better evidence on the source of resistant bacteria in animals and risks of transmission to humans, it is already evident that every combination has occurred of human to animal and animal to human transmissions, and resistances being acquired either pre- or post- transmission.  Research should focus on the relative risks of both emergence and transmission of resistance in health-care settings, the community, and livestock production to ensure resources are directed to where interventions will have maximum effect. The role of the environment (e.g. soil, water) in the development and transmission of resistance is another area where there is a need for better evidence.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 31.25pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Unlike for human medicine, there is not a mechanism established in the veterinary field for the collection and analysis of prescription data to allow an understanding of which different animal species have been treated, the treatment given, the purpose of the treatment and the </span><span style="font-family:'Times New Roman'; font-size:11pt">outcome.  Such information would be very powerful for improving responsible and optimal antibiotic use, and more meaningful comparison to human use.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q3. Is there sufficient research to invest in new antibiotics or other treatments and methods to ensure continued protection against infection?  If not, how could this be rectified?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">No, not for veterinary antibacterial products. The key disincentive to investment is uncertainty about future markets. In addition to the issues common with product development for human medicines, veterinary medicine producers face the additional risks of curtailment or banning of use of a new antibacterial based on the precautionary principal to reduce risk of resistance in human pathogens.  This could be despite absence of clinical resistance in veterinary practice and continued utility to treat animals.  Other factors different to human medicines include the additional costs involved in establishing maximum residue limits and conducting residue depletion studies (i.e. ensuring non or safe levels are in food) in each major food producing species together with the current lack of data protection for each target species. Another factor is that persistence of medicines in food producing animals will impact on the market; the shorter the persistence the sooner animals or their products can enter the food chain.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Cost of development and evaluation of antibacterial products continues to escalate, and expected expansion by regulatory bodies of tests to determine potential emergence of resistance will add to this burden, with improved determination unlikely for reasons explained in response to Q2.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Possible approaches to incentivising the market and easing approval would be to extend data and patent protection, and ensuring regulatory expectations for approval of a new antibiotic are firmly evidence based. The EU legislative framework for veterinary medicines is currently under review. The European Commission plans to publish proposals in the coming months. We anticipate that the proposals will include measures that lift some regulatory burdens and extend data protection.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Stimulation of development of novel alternatives (e.g. products that could “cure” bacteria of resistance so they become susceptible again to particular antibiotics) for veterinary medicine would create an economical in use proof-of-concept for latter consideration of human clinical trials.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q4. What measures (including behavioural change) have been most effective in controlling the spread of resistant pathogens, and could such measures be used to control other pathogens? </span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Methods to control the spread of pathogens are independent of their resistance status.  For both human and veterinary sectors infection control (called “biosecurity” for livestock production) is key.  Optimal infection control is the product of a combination of technology (equipment design) and behaviours (adherence to known best practice).  Maximum behaviour change is always achieved through a combination of education and peer pressure coupled with accountability and, where necessary, regulation/legislation.  Making hospital trust Chief </span><span style="font-family:'Times New Roman'; font-size:11pt">Executives accountable for MRSA and publishing MRSA infection rates (peer pressure) was a major contributor to the reductions achieved.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Publishing surveillance results and the impact of that transparency has been effective for hospital-acquired infections.  Something similar in the livestock area should be equally effective.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Another aspect of behaviour change in relation to antimicrobial resistance is good stewardship – in other words ensuring that antibiotics are prescribed and used responsibly in order to reduce the risk of the development of resistance through inappropriate use. In the EU, unlike in some parts of the world, antibiotics can only be obtained with a veterinary prescription and are not permitted as growth promoters in livestock production. Responsible prescribing and use are promoted, for example, through the Royal College of Veterinary Surgeon’s Code of Professional Conduct, prescribing guidelines published by the veterinary profession, practice-level prescribing policies and, to farmers, through guidance issued by the Responsible Use of Medicines in Agriculture Alliance. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q5. What global coordination and action is required to fight antimicrobial   resistance and is the UK contributing enough towards cross-border initiatives?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">There is much international co-operation and co-ordination, but this is mostly restricted to setting standards and harmonised testing protocols.  It is less at the level of agreeing common controls and interventions.   An exception to this is Europe where such controls for both human and veterinary medicines are set out in European Union legislation. </span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Within Europe the UK is leading on establishing a European surveillance programme for antibiotic resistance in veterinary pathogens.  Once established this should help provide evidence on a broader basis of the changing patterns of antibiotic susceptibility at the level of Member State and across Europe.  It will also provide the basis of an alerting mechanism, particularly for emergence of resistance to antibiotics considered to be of critical importance for humans.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">At the global level, there is an opportunity that could be exploited to help establish and/or improve regulation of veterinary medicines in developing countries.  However, it should be noted that in many of these countries there will be a tension between improving access to antibiotics for human health and their regulation to help control resistance.  This risk-benefit is different if more people die from lack of timely access to antibiotics than die because the bacterial pathogen was resistant.  More open access to antibiotics for human health unfortunately also means easier access for veterinary use.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">It is also the case that in some developed countries, the use of antibiotics for growth promotion is not prohibited. This practice was banned in 2006 within the EU.  This difference in practice provides opportunity for assessment of effectiveness.</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt"><br style="page-break-before:always; clear:both" /></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Q6. What are the strengths and weaknesses of the Government’s 2013-18 strategy for tacking antimicrobial resistance?  What changes might be made to further strengthen the Government’s action plan?</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The VMD has contributed to the Department of Health’s response to the Committee’s call for evidence.  The only additional points we would wish to add here are:</span></li></ol><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 57.75pt; text-align:justify; text-indent:-21.75pt"><span style="font-family:'Times New Roman'; font-size:11pt">(a)</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The involvement of the human and veterinary disciplines in a one-health   approach is a strength.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 57.75pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">(b) The difficulty of cause and effect attribution and absence of models to predict outcome if no action is taken is a weakness which will make it difficult to measure outcome success and to identify which actions are most productive. Nevertheless, this should not prevent us from taking common sense actions. Equally this should not push policy-makers towards an extreme precautionary approach.</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">November 2013</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">              </span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:115%; margin:0pt 0pt 10pt 36pt; text-align:justify; text-indent:-36pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:right"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>